BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...
BOULDER, Colo.--(BUSINESS WIRE)--Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of SHORTEN-ctDNA, a clinical trial ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
For patients with diffuse large B-cell lymphoma (DLBCL), the detection of circulating tumor DNA (ctDNA) following first-line treatment is independently predictive of disease recurrence and overall ...
Dr. Hua-Jay Cherng, a hematologist oncologist at NewYork-Presbyterian/Columbia University Medical Center, discussed how ctDNA ...
Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of ...
The combination of Epkinly and R-mini-CHOP showed a 93% ORR and 86% CR rate in elderly DLBCL patients. At two years, 79% of patients remained in complete response, with a 76% progression-free survival ...
About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...
Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results